Loading…
Bayesian inference for prediction of survival probability in prime‐boost vaccination regimes
We focus on Bayesian inference for survival probabilities in a prime‐boost vaccination regime in the development of an Ebola vaccine. We are interested in the heterologous prime‐boost regimen (unmatched vaccine deliverys using the same antigen) due to its demonstrated durable immunity, well‐tolerate...
Saved in:
Published in: | Statistics in medicine 2024-02, Vol.43 (3), p.560-577 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c3102-9c122e22d0571ae0aea677853b5c15396e43e5bb89de9bcf702be4b1740798ce3 |
container_end_page | 577 |
container_issue | 3 |
container_start_page | 560 |
container_title | Statistics in medicine |
container_volume | 43 |
creator | Lu, Yuelin Carlin, Bradley P. Seaman, John W. |
description | We focus on Bayesian inference for survival probabilities in a prime‐boost vaccination regime in the development of an Ebola vaccine. We are interested in the heterologous prime‐boost regimen (unmatched vaccine deliverys using the same antigen) due to its demonstrated durable immunity, well‐tolerated safety profile, and suitability as a population vaccination strategy. Our research is motivated by the need to estimate the survival probability given the administered dosage. To do so, we establish two key relationships. Firstly, we model the connection between the designed dose concentration and the induced antibody count using a Bayesian response surface model. Secondly, we model the association between the antibody count and the probability of survival when experimental subjects are exposed to the Ebola virus in a controlled setting using a Bayesian probability of survival model. Finally, we employ a combination of the two models with dose concentration as the predictor of the survival probability for a future vaccinated population. We implement our two‐level Bayesian model in Stan, and illustrate its use with simulated and real‐world data. Performance of this model is evaluated via simulation. Our work offers a new application of drug synergy models to examine prime‐boost vaccine efficacy, and does so using a hierarchical Bayesian framework that allows us to use dose concentration to predict survival probability. |
doi_str_mv | 10.1002/sim.9972 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2903859515</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2913344983</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3102-9c122e22d0571ae0aea677853b5c15396e43e5bb89de9bcf702be4b1740798ce3</originalsourceid><addsrcrecordid>eNp1kM1KAzEQx4MotlbBJ5AFL15W87FpNkctfkHFg3oOSTorKduNJt3K3nwEH8Fn8VF8EtP6BYKngZnf_Jj5I7RL8CHBmB5FNzuUUtA11CdYihxTXq6jPqZC5ENBeA9txTjFmBBOxSbqsXKJYdFH6kR3EJ1uMtdUEKCxkFU-ZA8BJs7OnW8yX2WxDQu30HVqe6ONq928Swtvrw_BzeD9-cV4H-fZQlvrGr3aCnCfRnEbbVS6jrDzVQfo7uz0dnSRj6_PL0fH49wygmkuLaEUKJ1gLogGrEEPhSg5M9wSzuQQCgbcmFJOQBpbCUwNFIaIAgtZWmADdPDpTRc-thDnauaihbrWDfg2KioxK7nkSTZA-3_QqW9Dk65LFGGsKGTJfoU2-BgDVGr5qw6dIlgtQ1cpdLUMPaF7X8LWzGDyA36nnID8E3hyNXT_itTN5dVK-AHgxo15</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2913344983</pqid></control><display><type>article</type><title>Bayesian inference for prediction of survival probability in prime‐boost vaccination regimes</title><source>Wiley</source><creator>Lu, Yuelin ; Carlin, Bradley P. ; Seaman, John W.</creator><creatorcontrib>Lu, Yuelin ; Carlin, Bradley P. ; Seaman, John W.</creatorcontrib><description>We focus on Bayesian inference for survival probabilities in a prime‐boost vaccination regime in the development of an Ebola vaccine. We are interested in the heterologous prime‐boost regimen (unmatched vaccine deliverys using the same antigen) due to its demonstrated durable immunity, well‐tolerated safety profile, and suitability as a population vaccination strategy. Our research is motivated by the need to estimate the survival probability given the administered dosage. To do so, we establish two key relationships. Firstly, we model the connection between the designed dose concentration and the induced antibody count using a Bayesian response surface model. Secondly, we model the association between the antibody count and the probability of survival when experimental subjects are exposed to the Ebola virus in a controlled setting using a Bayesian probability of survival model. Finally, we employ a combination of the two models with dose concentration as the predictor of the survival probability for a future vaccinated population. We implement our two‐level Bayesian model in Stan, and illustrate its use with simulated and real‐world data. Performance of this model is evaluated via simulation. Our work offers a new application of drug synergy models to examine prime‐boost vaccine efficacy, and does so using a hierarchical Bayesian framework that allows us to use dose concentration to predict survival probability.</description><identifier>ISSN: 0277-6715</identifier><identifier>EISSN: 1097-0258</identifier><identifier>DOI: 10.1002/sim.9972</identifier><identifier>PMID: 38109707</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Bayes Theorem ; Bayesian analysis ; Bayesian hierarchical model ; dose–response modeling ; Ebola Vaccines - pharmacology ; Ebola virus ; Hemorrhagic Fever, Ebola - prevention & control ; heterologous vaccination ; Humans ; Immunization, Secondary ; Probability ; Survival analysis ; Vaccination ; Vaccines</subject><ispartof>Statistics in medicine, 2024-02, Vol.43 (3), p.560-577</ispartof><rights>2023 John Wiley & Sons Ltd.</rights><rights>2024 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3102-9c122e22d0571ae0aea677853b5c15396e43e5bb89de9bcf702be4b1740798ce3</cites><orcidid>0000-0002-0684-8753 ; 0000-0002-0701-4929</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38109707$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lu, Yuelin</creatorcontrib><creatorcontrib>Carlin, Bradley P.</creatorcontrib><creatorcontrib>Seaman, John W.</creatorcontrib><title>Bayesian inference for prediction of survival probability in prime‐boost vaccination regimes</title><title>Statistics in medicine</title><addtitle>Stat Med</addtitle><description>We focus on Bayesian inference for survival probabilities in a prime‐boost vaccination regime in the development of an Ebola vaccine. We are interested in the heterologous prime‐boost regimen (unmatched vaccine deliverys using the same antigen) due to its demonstrated durable immunity, well‐tolerated safety profile, and suitability as a population vaccination strategy. Our research is motivated by the need to estimate the survival probability given the administered dosage. To do so, we establish two key relationships. Firstly, we model the connection between the designed dose concentration and the induced antibody count using a Bayesian response surface model. Secondly, we model the association between the antibody count and the probability of survival when experimental subjects are exposed to the Ebola virus in a controlled setting using a Bayesian probability of survival model. Finally, we employ a combination of the two models with dose concentration as the predictor of the survival probability for a future vaccinated population. We implement our two‐level Bayesian model in Stan, and illustrate its use with simulated and real‐world data. Performance of this model is evaluated via simulation. Our work offers a new application of drug synergy models to examine prime‐boost vaccine efficacy, and does so using a hierarchical Bayesian framework that allows us to use dose concentration to predict survival probability.</description><subject>Bayes Theorem</subject><subject>Bayesian analysis</subject><subject>Bayesian hierarchical model</subject><subject>dose–response modeling</subject><subject>Ebola Vaccines - pharmacology</subject><subject>Ebola virus</subject><subject>Hemorrhagic Fever, Ebola - prevention & control</subject><subject>heterologous vaccination</subject><subject>Humans</subject><subject>Immunization, Secondary</subject><subject>Probability</subject><subject>Survival analysis</subject><subject>Vaccination</subject><subject>Vaccines</subject><issn>0277-6715</issn><issn>1097-0258</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp1kM1KAzEQx4MotlbBJ5AFL15W87FpNkctfkHFg3oOSTorKduNJt3K3nwEH8Fn8VF8EtP6BYKngZnf_Jj5I7RL8CHBmB5FNzuUUtA11CdYihxTXq6jPqZC5ENBeA9txTjFmBBOxSbqsXKJYdFH6kR3EJ1uMtdUEKCxkFU-ZA8BJs7OnW8yX2WxDQu30HVqe6ONq928Swtvrw_BzeD9-cV4H-fZQlvrGr3aCnCfRnEbbVS6jrDzVQfo7uz0dnSRj6_PL0fH49wygmkuLaEUKJ1gLogGrEEPhSg5M9wSzuQQCgbcmFJOQBpbCUwNFIaIAgtZWmADdPDpTRc-thDnauaihbrWDfg2KioxK7nkSTZA-3_QqW9Dk65LFGGsKGTJfoU2-BgDVGr5qw6dIlgtQ1cpdLUMPaF7X8LWzGDyA36nnID8E3hyNXT_itTN5dVK-AHgxo15</recordid><startdate>20240210</startdate><enddate>20240210</enddate><creator>Lu, Yuelin</creator><creator>Carlin, Bradley P.</creator><creator>Seaman, John W.</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0684-8753</orcidid><orcidid>https://orcid.org/0000-0002-0701-4929</orcidid></search><sort><creationdate>20240210</creationdate><title>Bayesian inference for prediction of survival probability in prime‐boost vaccination regimes</title><author>Lu, Yuelin ; Carlin, Bradley P. ; Seaman, John W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3102-9c122e22d0571ae0aea677853b5c15396e43e5bb89de9bcf702be4b1740798ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Bayes Theorem</topic><topic>Bayesian analysis</topic><topic>Bayesian hierarchical model</topic><topic>dose–response modeling</topic><topic>Ebola Vaccines - pharmacology</topic><topic>Ebola virus</topic><topic>Hemorrhagic Fever, Ebola - prevention & control</topic><topic>heterologous vaccination</topic><topic>Humans</topic><topic>Immunization, Secondary</topic><topic>Probability</topic><topic>Survival analysis</topic><topic>Vaccination</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lu, Yuelin</creatorcontrib><creatorcontrib>Carlin, Bradley P.</creatorcontrib><creatorcontrib>Seaman, John W.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Statistics in medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lu, Yuelin</au><au>Carlin, Bradley P.</au><au>Seaman, John W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bayesian inference for prediction of survival probability in prime‐boost vaccination regimes</atitle><jtitle>Statistics in medicine</jtitle><addtitle>Stat Med</addtitle><date>2024-02-10</date><risdate>2024</risdate><volume>43</volume><issue>3</issue><spage>560</spage><epage>577</epage><pages>560-577</pages><issn>0277-6715</issn><eissn>1097-0258</eissn><abstract>We focus on Bayesian inference for survival probabilities in a prime‐boost vaccination regime in the development of an Ebola vaccine. We are interested in the heterologous prime‐boost regimen (unmatched vaccine deliverys using the same antigen) due to its demonstrated durable immunity, well‐tolerated safety profile, and suitability as a population vaccination strategy. Our research is motivated by the need to estimate the survival probability given the administered dosage. To do so, we establish two key relationships. Firstly, we model the connection between the designed dose concentration and the induced antibody count using a Bayesian response surface model. Secondly, we model the association between the antibody count and the probability of survival when experimental subjects are exposed to the Ebola virus in a controlled setting using a Bayesian probability of survival model. Finally, we employ a combination of the two models with dose concentration as the predictor of the survival probability for a future vaccinated population. We implement our two‐level Bayesian model in Stan, and illustrate its use with simulated and real‐world data. Performance of this model is evaluated via simulation. Our work offers a new application of drug synergy models to examine prime‐boost vaccine efficacy, and does so using a hierarchical Bayesian framework that allows us to use dose concentration to predict survival probability.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>38109707</pmid><doi>10.1002/sim.9972</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0002-0684-8753</orcidid><orcidid>https://orcid.org/0000-0002-0701-4929</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0277-6715 |
ispartof | Statistics in medicine, 2024-02, Vol.43 (3), p.560-577 |
issn | 0277-6715 1097-0258 |
language | eng |
recordid | cdi_proquest_miscellaneous_2903859515 |
source | Wiley |
subjects | Bayes Theorem Bayesian analysis Bayesian hierarchical model dose–response modeling Ebola Vaccines - pharmacology Ebola virus Hemorrhagic Fever, Ebola - prevention & control heterologous vaccination Humans Immunization, Secondary Probability Survival analysis Vaccination Vaccines |
title | Bayesian inference for prediction of survival probability in prime‐boost vaccination regimes |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T15%3A15%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bayesian%20inference%20for%20prediction%20of%20survival%20probability%20in%C2%A0prime%E2%80%90boost%20vaccination%20regimes&rft.jtitle=Statistics%20in%20medicine&rft.au=Lu,%20Yuelin&rft.date=2024-02-10&rft.volume=43&rft.issue=3&rft.spage=560&rft.epage=577&rft.pages=560-577&rft.issn=0277-6715&rft.eissn=1097-0258&rft_id=info:doi/10.1002/sim.9972&rft_dat=%3Cproquest_cross%3E2913344983%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3102-9c122e22d0571ae0aea677853b5c15396e43e5bb89de9bcf702be4b1740798ce3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2913344983&rft_id=info:pmid/38109707&rfr_iscdi=true |